Eli Lilly (LLY) · Deep analysis

Report previewLLY.USReport date Last updated
← Back to reports
Report contents

At a glance

  • Business model: Lilly sells branded prescription medicines and is paid mainly by insurers, pharmacy benefit managers, and government health programs; tirzepatide, sold as Mounjaro and Zepbound, drives the results. Volume is its leverage, not price: the June 2026 quarter grew revenue 48% on 60% volume growth against a 13% price decline.
  • Financial quality: Reported profitability is exceptional: gross margin was 83.8% in FY2025 and 85.8% in the June 2026 quarter. Cash conversion is the reservation, since operating cash flow covered only 0.81 of net income in each of FY2023 through FY2025; debt-to-assets of 76.2% is high, though short-term debt was covered by cash.
01

Business model

Business model: incretin volume carries the earnings

Eli Lilly is a research-based branded drugmaker. It discovers, patents, and manufactures prescription medicines, sells them through wholesalers and distributors, and is paid by the insurers, pharmacy benefit managers, and government health programs that decide whether patients can have the product and on what terms. Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity, is the business that matters: Lilly reported revenue up 48% in the June 2026 quarter on 60% volume growth against a 13% price decline. Oncology, immunology, and the older diabetes portfolio are smaller. The customer is the payer, the market is mostly the United States and other developed countries, and the stage is expansion.

Payers set the price; patients only set the volume

Demand has not been the binding constraint. Lilly's reported U.S. price decline of about 3% in the June 2026 quarter widened to roughly 9% once adjustments to rebate and discount estimates were folded in. That gap is the commercial model in miniature: a list price is an opening position, and payers negotiate down from it. Because the difference runs through an accrual, reported price and gross margin can move for reasons that have nothing to do with a renegotiation. What has kept gross margin near 80% is manufacturing cost and product mix, not pricing power over the patient. Volume is Lilly's leverage; price is where its customers have theirs, and broader formulary access costs net price in exchange for patients.

Two customer groups sit behind that number. Commercial insurers and their pharmacy benefit managers negotiate hardest on the obesity brand, where coverage rules are least settled, while government programs price by formula. Mix between those channels moves average net price even when no individual contract changes.

Volume growth is not yet a compounding patient base

Sixty percent volume growth is a revenue fact. It does not establish that the patient base compounds: Lilly reports volume and price, not how long patients stay on therapy. Persistence is visible only through third-party prescription data, and if a large share of starts discontinue within a year, each year's revenue depends on refilling the funnel instead of on a durable installed base. Competition attacks the same funnel. A rival incretin or an oral alternative takes share at the margin first, and formulary decisions determine which product a new patient is offered, so coverage wins matter more than any individual launch. None of this has slowed reported growth yet. The quarterly split between volume and price is the clearest test of whether it is starting to.

The capital is committed before the demand is proven

Lilly is building as if the franchise keeps compounding. It added $4.5 billion to its Indiana manufacturing commitment, inventory turns fell from 1.86 in fiscal 2021 to 1.26 in fiscal 2024 as stock was built ahead of demand, and operating cash flow covered only 0.81 of net income in each of fiscal 2023 through 2025. From fiscal 2021 through fiscal 2025, cumulative free cash flow of $16.2 billion came against $48.3 billion of net income. That is what an expansion phase looks like when supply is scarce and the plants are not yet running. The risk is asymmetric: capacity, inventory, and the depreciation that follows are committed now, so slower volume would leave fixed costs against weaker sales. Falling unit costs as new lines qualify are the offset, and they matter more with every quarter of price decline.

A second engine is being bought, not yet built

Beyond internal research, Lilly has been buying pipeline. In the June 2026 quarter it recorded $3.03 per share of acquired in-process research and development charges (the immediate write-off of bought drug programs that are not yet approved), against $0.14 a year earlier, and goodwill rose to $8.85 billion from $5.90 billion in December 2025. Dealmaking is a legitimate way to widen the product base, but a purchased program is a claim on future revenue, not revenue. The charge hits earnings immediately while any payoff arrives years later and may never arrive. Until an acquired asset reaches the market in a large indication, the mix stays what it is.

What would change the judgment

The working view is that Lilly is a single-franchise branded manufacturer in an expansion phase, funded by volumes still growing faster than prices fall, with payers taking a rising share of list price and the capital budget committed ahead of demand. Two observations would overturn it. A non-incretin product line reaching a material share of revenue would make the mix less binary and earnings less hostage to tirzepatide's exclusivity. Several consecutive quarters in which rebates and discounts take a larger share of gross price would mean the franchise earns less per patient even as volume grows, which is a different business from the one the growth rate implies. One quarter settles neither.

Questions worth following

  • Can Lilly keep preferred payer coverage for its incretin drugs without conceding deeper rebates?

    Formulary terms decide the net price Lilly collects on its largest franchise. If coverage holds without larger concessions, pricing power supports margins and the case for the incretin profit pool. If rebates deepen to defend access, revenue can grow while unit economics deteriorate.

  • Will oral GLP-1 therapies take first-line obesity starts from injectable tirzepatide?

    First-line prescribing determines the size of the injectable base for years and the rebate terms attached to it. A shift toward orals would compress the franchise's share of new patients even if total market volume keeps growing, changing both mix and the cost structure behind it.

  • Can Lilly's manufacturing buildout keep incretin supply ahead of demand without stranding capacity?

    Tirzepatide demand must be met with capacity committed years earlier. Slippage limits revenue and cedes share to rivals; overbuilding leaves fixed costs without volume. The answer shapes both the growth rate and the return on the capital Lilly is deploying.

02

Financial quality

Financial quality: profitability still outruns cash conversion

Core financial quality: Strong, with two reservations. Lilly’s product economics are exceptional: gross margin reached 83.8% in FY2025 and 85.8% in the June 2026 quarter, while net margin was 31.7% in FY2025. But cash conversion has run below reported earnings for three years, and the liability base remains high. The result is a strong earnings engine that still requires close attention to working capital, deal costs and debt-funded expansion.

Annual performance and latest quarter
PeriodFY2021FY2022FY2023FY2024FY2025Q2 FY26Assessment
Revenue (USD bn)28.3228.5434.1245.0465.1822.97Strong
Net income (USD bn)5.586.255.2410.5920.647.10Exceptional
Gross margin (%)74.276.879.281.383.885.8Exceptional
Net margin (%)19.721.915.423.531.730.9Exceptional
ROE (%)76.463.648.984.877.821.0Exceptional
Debt-to-assets (%)81.278.283.081.976.476.2Weak
Current ratio1.231.050.941.15Not disclosedNot disclosedAdequate
Inventory turnover1.861.541.401.26Not disclosedNot disclosedWeak
Operating cash flow (USD bn)7.267.084.248.8216.8110.69Strong
Operating cash flow / net income1.301.130.810.830.811.51Adequate
Free cash flow (USD bn)5.394.60-3.150.418.977.76Adequate

*Q2 FY26 is a single quarter; flows are not annualized.

Quarterly trend
PeriodRevenue (USD bn)Net income (USD bn)Gross margin (%)Total assets (USD bn)Total liabilities (USD bn)Net PP&E (USD bn)Operating cash flow (USD bn)AssessmentTrend
FY25 Q112.732.7682.589.3973.5418.471.67AdequateImproving; revenue and net income rising
FY25 Q215.565.6684.3100.9282.57Not disclosed3.09StrongRevenue up 22% q/q; OCF higher
FY25 Q317.605.5882.9114.9391.09Not disclosed8.84StrongOCF spike; net income flat q/q
FY25 Q419.296.6485.1112.4885.94Not disclosed3.23StrongRevenue up; OCF seasonally lower
FY26 Q119.807.4081.9116.5885.38Not disclosed5.33StrongNet income higher; liabilities dip
FY26 Q222.977.1085.8142.28108.40Not disclosed10.69StrongAcquisition lifts assets and liabilities; OCF strong

Profitability: Exceptional. Gross margin has expanded from 74.2% in FY2021 to 83.8% in FY2025 even as realized prices are falling on the key incretin products. In the Q3 2026 release, Lilly reported 39% revenue growth with a 53% volume increase and a 15% realized price decline. That combination is sustainable only if manufacturing scale and mix keep lowering cost per unit. The Q3 release also said about $900 million of revenue benefits were tied to Jardiance milestones and rebate accrual adjustments, so a portion of the quarter’s margin strength was not ordinary recurring patient demand.

Cash conversion: Improving, but not yet proven. Operating cash flow covered net income only 0.81 times in FY2023, FY2024 and FY2025. Free cash flow was $8.97 billion in FY2025, far below the $20.64 billion of net income, because Lilly is spending heavily on manufacturing capacity and carrying more inventory. Inventory turnover fell from 1.86 in FY2021 to 1.26 in FY2024, consistent with the supply build ahead of demand. The June 2026 quarter shows a sharper conversion, with operating cash flow of $10.69 billion against net income of $7.10 billion, but one quarter does not settle whether the multiyear gap has closed.

Leverage: High, but near-term liquidity is adequate. Debt-to-assets remains around 76%, and total equity of $33.88 billion supports a much larger $142.28 billion asset base. That leverage magnifies the reported returns on equity; it also means a modest decline in asset values would hit equity disproportionately. Short-term debt of $7.05 billion in Q2 FY26 was slightly below cash of $8.95 billion, so the immediate refinancing risk looks manageable. The larger question is whether the liability base contains enough non-debt items such as rebate accruals and payables to make the 76% ratio less threatening than it first appears.

Earnings quality: acquired IPR&D is becoming a recurring charge. Lilly’s Q3 2026 report included $4.57 of acquired IPR&D charges, compared with $0.71 in Q3 2025. Goodwill rose from $5.90 billion in December 2025 to $8.85 billion by June 2026, and the company completed further deals after the quarter. Those charges reduce reported profit immediately even though the cash is an investing outflow. If dealmaking continues at this pace, historical comparisons of net income will keep requiring adjustment, and the earnings stream will depend on whether acquired programs eventually produce revenue.

Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.

Go beyond the preview

Continue reading the full report

  1. Key risksWhat could break the investment case
  2. Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
  3. SummaryOur overall judgement and what to watch next

Free to sign up · 20 research points · unlocking this report uses 10

20 points cover 2 full reports. No card needed.

Research reflects its generation date. Preview the first two modules.

More on Eli Lilly and Company